Patents by Inventor Derek Jantz

Derek Jantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
    Publication number: 20190233500
    Abstract: The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition. For example, disclosed herein are genetically-modified cells comprising a chimeric antigen receptor or an inducible regulatory construct incorporating the co-stimulatory domains disclosed herein. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the co-stimulatory domains, and methods of administering compositions comprising the novel co-stimulatory domains to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.
    Type: Application
    Filed: October 4, 2017
    Publication date: August 1, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, Aaron Martin, Jeffrey Sunman, Daniel T. MacLeod
  • RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF
    Publication number: 20190194729
    Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-CreI-derived meganuclease business.
    Type: Application
    Filed: March 11, 2019
    Publication date: June 27, 2019
    Inventors: Derek Jantz, James Jefferson Smith
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20190194616
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: October 2, 2018
    Publication date: June 27, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A
    Publication number: 20190142973
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating hemophilia A. Further, the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins, nucleic acids encoding engineered nucleases, or genetically-modified cells of the invention, and the use of such compositions for treating of hemophilia A.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 16, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Victor Bartsevich, Clayton Beard, Michael G. Nicholson
  • Recognition sequences for I-CreI-derived meganucleases and uses thereof
    Patent number: 10287626
    Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-CreI-derived meganuclease business.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: May 14, 2019
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith
  • Recognition sequences for I-CreI-derived meganucleases and uses thereof
    Patent number: 10273524
    Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-CreI-derived meganuclease business.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 30, 2019
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith
  • ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE
    Publication number: 20190017075
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human beta-2 microglobulin gene. The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified T cells having reduced cell-surface expression of beta-2 microglobulin.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 17, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Christina Pham, Aaron Martin, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES
    Publication number: 20180344817
    Abstract: The present invention provides a method of treating a nucleotide repeat expansion disorder comprising delivering a pair of engineered nucleases, or genes encoding engineered nucleases, to the cells of a patient such that the two nucleases excise the nucleotide repeat responsible for the disease permanently from the genome. The invention provides a general method for treating nucleotide repeat expansion disorders and engineered nucleases suitable for practicing the method. The invention further provides vectors and techniques for delivering engineered nucleases to patient cells.
    Type: Application
    Filed: May 2, 2016
    Publication date: December 6, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Victor Bartsevich, Derek Jantz
  • RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
    Publication number: 20180340160
    Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 29, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Derek Jantz
  • METHODS FOR PRODUCING A COMPLEX TRANSGENIC TRAIT LOCUS
    Publication number: 20180305706
    Abstract: Methods for producing in a plant a complex transgenic trait locus comprising at least two altered target sequences in a genomic region of interest are disclosed. The methods involve the use of two or more double-strand-break-inducing agents, each of which can cause a double-strand break in a target sequence in the genomic region of interest which results in an alteration in the target sequence. Also disclosed are complex transgenic trait loci in plants. A complex transgenic trait locus comprises at least two altered target sequences that are genetically linked to a polynucleotide of interest. Plants, plant cells, plant parts, and seeds comprising one or more complex transgenic trait loci are also disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 25, 2018
    Applicants: PIONEER HI-BRED INTERNATIONAL, INC., E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Andrew Mark Cigan, Saverio Carl Falco, Huirong Gao, Michael Lassner, Derek Jantz, Zhongsen Li, Zhan-Bin Liu, Sergei Svitashev, James Jefferson Smith
  • ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180289741
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 11, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093900
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093899
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180265845
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 20, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180258392
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 13, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
    Publication number: 20180250370
    Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
    Type: Application
    Filed: September 8, 2016
    Publication date: September 6, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
    Patent number: 10041053
    Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: August 7, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Derek Jantz
  • Methods for producing a complex transgenic trait locus
    Patent number: 10030245
    Abstract: Methods for producing in a plant a complex transgenic trait locus comprising at least two altered target sequences in a genomic region of interest are disclosed. The methods involve the use of two or more double-strand-break-inducing agents, each of which can cause a double-strand break in a target sequence in the genomic region of interest which results in an alteration in the target sequence. Also disclosed are complex transgenic trait loci in plants. A complex transgenic trait locus comprises at least two altered target sequences that are genetically linked to a polynucleotide of interest. Plants, plant cells, plant parts, and seeds comprising one or more complex transgenic trait loci are also disclosed.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: July 24, 2018
    Assignees: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Michael Lassner, Derek Jantz, James Jefferson Smith, Mark Cigan, Carl Falco, Huirong Gao, Zhongsen Li, Zhan-Bin Liu, Sergei Svitashev
  • SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES
    Publication number: 20180171357
    Abstract: Disclosed herein are viral vectors for use in recombinant molecular biology techniques. In particular, the present disclosure relates to self-limiting viral vectors comprising genes encoding site-specific endonucleases as well as recognition sequences for site-specific endonucleases such that expression of the endonuclease in a cell cleaves the viral vector and limits its persistence time. In some embodiments, the viral vectors disclosed herein also carry directives to delete, insert, or change a target sequence.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 21, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
    Publication number: 20180163233
    Abstract: Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed. In particular, sequences of interest (e.g., genes encoding biotherapeutic proteins) are inserted proximal to selectable genes in amplifiable loci, and the transformed cells are subjected to selection to induce co-amplification of the selectable gene and the sequence of interest. The invention also relates to meganucleases, vectors and engineered cell lines necessary for performing the methods, to cell lines resulting from the application of the methods, and use of the cell lines to produce protein products of interest.
    Type: Application
    Filed: October 13, 2017
    Publication date: June 14, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson